Inactief instrument

Koers Occlutech Holding AG

Aandelen

Duur

Periode

Stijl

Occlutech Holding AG blijft vooruitgang boeken in US FDA studie OCCLUFLEX – neemt eerste patiënt op in Europa	31-01-23	CI
Occlutech Holding AG benoemt Jozef Bartunek tot nieuwe Chief Medical Officer	01-11-22	CI
Occlutech Holding AG benoemt Jose De La Cortina tot Chief Commercial Officer	06-09-22	CI

Occlutech Holding AG Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe	31-01-23
Occlutech Holding AG Appoints Jozef Bartunek as New Chief Medical Officer	01-11-22
Occlutech Holding AG Appoints Jose De La Cortina as Chief Commercial Officer	06-09-22
Occlutech Holding AG announced that it has received SEK 450 million in funding from AP Fonden 4, Carnegie Investment Bank AB	21-12-21
Occlutech Holding AG has withdrawn its IPO in the amount of SEK 963.8035 million.	28-09-21

Sector